First Choice Neurology

First Choice Neurology Research Center 32 Clinical Trials

First Choice Neurology Research Center 32 offers clinical trials for Migraines, Alzheimer’s disease, Hypotension, Multiple Sclerosis, Parkinson’s disease, Epilepsy, and other neurological disorders.


Migraine Clinical Studies

Biohaven BHV3500-302
A phase 2/3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Zavegepant in migraine prevention.

Biohaven BHV3000-404
A phase 4 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety or Rimegepant in episodic migraine prevention with multiple dosing regimens.

Abbvie M22-418
Chronic Migraine: A phase 3 multicenter 24-week open-label study to evaluate the safety, tolerability, and efficacy of Atogepant when added to OnabotulinumtoxinA (BOTOX) for the prevention of treatment of chronic migraine.

Abbvie M21-307
Episodic Migraine: Phase 3 study of BOTOX (Botulinum Toxin Type A) for the prevention of migraine in subjects with episodic migraine.

Satsuma STS101-007
A randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of STS101 (Dihydroergotamine Nasal Powder) in the acute treatment of Migraine.

 

Florida medical research centers


Alzheimer's Disease Clinical Studies

Eli Lilly I9X-MC-MTAE
Assessment of safety, tolerability, and efficacy of LY3372689 in early symptomatic Alzheimer’s Disease.

Cassava PTI-125-07
A phase 3, randomized, double-blind, placebo-controlled, parallel-group, 52-week study evaluating the safety and efficacy of Simufilam 100mg tablets in subjects with mild-to-moderate Alzheimer’s Disease.

Eli Lilly I5T-MC-AACM
A study of donanemab versus placebo in participants at risk for cognitive and functional decline for Alzheimer’s Disease.


Multiple Sclerosis Clinical Studies

Celgene RPC-1063-MS-001- A multicenter, longitudinal, open-label, single-arm study describing cognitive processing speed changes in relapsing multiple sclerosis subjects treated with Ozanimod (RPC-1063).


Contact First Choice Neurology Research Center 32

Neurology Office of South Florida, LLC
9970 Central Park Blvd., Suite 207
Boca Raton, FL 33428
Phone: (561) 482-1027
Fax: (561) 482-1028

Providers:
Brian Costell, MD
Meghan Jacobs, PsyD
Carol Eickhorn, ARNP

Contact:
Cody Paauwe, CRC
(561) 482-1027 ext. 9
cpaauwe@fcneurology.net

Translate »